Chimeric Therapeutics is trading approximately 6% down today at A$0.05 as the stock pulls back despite reporting encouraging interim clinical data.
- Phase 1 trial results for its gastrointestinal cancer CAR-T therapy showed 17–40% tumour shrinkage in high-dose patients and durable stable disease.
- The decline appears driven by broader weakness in the biotech sector and profit-taking following prior gains rather than a reaction to negative company news.